Esperion Therapeutics (NASDAQ:ESPR) Reaches New 1-Year High – Still a Buy?

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) reached a new 52-week high on Monday . The stock traded as high as $3.44 and last traded at $3.43, with a volume of 8108749 shares. The stock had previously closed at $2.80.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ESPR. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, November 27th. Needham & Company LLC dropped their price target on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, August 13th. Finally, StockNews.com cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Esperion Therapeutics Price Performance

The firm has a 50-day simple moving average of $2.11 and a 200-day simple moving average of $2.16. The firm has a market capitalization of $610.82 million, a PE ratio of -4.64 and a beta of 0.96.

Institutional Trading of Esperion Therapeutics

Large investors have recently added to or reduced their stakes in the business. Wasatch Advisors LP increased its position in Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after buying an additional 6,483,070 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Esperion Therapeutics by 71.8% during the 1st quarter. Vanguard Group Inc. now owns 8,826,546 shares of the biopharmaceutical company’s stock valued at $23,655,000 after acquiring an additional 3,688,796 shares during the period. Geode Capital Management LLC increased its holdings in Esperion Therapeutics by 4.1% in the 3rd quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock worth $7,148,000 after acquiring an additional 171,609 shares in the last quarter. Marshall Wace LLP raised its stake in Esperion Therapeutics by 94.2% during the 2nd quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock worth $9,554,000 after acquiring an additional 2,087,635 shares during the period. Finally, State Street Corp lifted its holdings in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares in the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.